The Benchmark Company, LLC
150 E 58th Street, 17th floor
New York, NY 10155
Dawson James Securities, Inc.
1 North Federal Highway, 5th Floor
Boca Raton, FL 33432
December 19, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Acasti Pharma, Inc. (the “Company”) |
Registration Statement on FormF-1
FileNo. 333-220755
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as underwriter of the proposed offering, hereby joins the request of Acasti Pharma, Inc. that the effective date of the above-referenced Registration Statement on FormF-1 be declared effective at 4:30 p.m. (Washington, D.C. time) on Tuesday, December 19, 2017, or as soon as practicable thereafter.
In connection with this acceleration request and pursuant to Rule 460 under the Securities Act, please be advised that between December 15, 2017 and the date hereof, approximately 1,350 copies of the preliminary prospectus dated December 14, 2017 were distributed to underwriters, dealers, institutions and others.
The undersigned advise that the underwriters have complied and will continue to comply with Rule15c2-8 under the Securities Exchange Act of 1934, as amended.
Sincerely,
The Benchmark Company, LLC | ||
| By: | /s/ John J. Borer | |
| Name: | John J. Borer | |
| Title: | Senior Managing Director | |
| Dawson James Securities, Inc. | ||
| By: | /s/ Robert D. Keyser, Jr. | |
| Name: | Robert D. Keyser, Jr. | |
| Title: | CEO | |
